Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$195.45 USD

195.45
3,453,379

-1.37 (-0.70%)

Updated Oct 3, 2024 04:00 PM ET

Pre-Market: $195.00 -0.45 (-0.23%) 9:12 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Biohaven (BHVN) Q1 Earnings Miss, Nurtec Uptake Remains Strong

Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine continues to demonstrate strong demand in the United States. Higher operating expense drags down the bottom line.

ImmunoGen (IMGN) Q1 Earnings Top, Pivotal Studies Delayed

ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates. Meanwhile, data readouts from pivotal studies on lead candidate get delayed due to COVID-19. Stock down.

Ironwood's (IRWD) Q1 Earnings Beat, 2021 Guidance Muted

Ironwood (IRWD) witnesses strong demand for Linzess in the first quarter. However, outlook for 2021 misses market expectations. Stock down.

Reata's (RETA) Q1 Earnings Beat Estimates, Revenues Miss

Reata (RETA) reports mixed first-quarter results wherein earnings beat estimates but sales miss the same. Stock rises.

Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year?

Is (ABBV) Outperforming Other Medical Stocks This Year?

AbbVie (ABBV) Stock Moves -0.61%: What You Should Know

AbbVie (ABBV) closed at $113.98 in the latest trading session, marking a -0.61% move from the prior day.

Kinjel Shah headshot

3 Big Drugmaker Stocks to Watch Out For Amid Pandemic Woes

Most Large Cap Pharmaceuticals industry players' Q1 results have been disappointing. Launch of COVID-19 vaccines and medicines is playing a crucial role in driving the industry. PFE, JNJ and AZN may prove to be good additions to your portfolio.

AbbVie (ABBV) Beats on Q1 Earnings, Raises 2021 Guidance

AbbVie (ABBV) beats on first-quarter 2021 earnings and revenues. Shares up in pre-market trading.

AbbVie (ABBV) Surpasses Q1 Earnings and Revenue Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of 6.50% and 0.51%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Tracey Ryniec headshot

5 Big Cap Earnings Superstars

It's not easy for companies to beat on earnings nearly every quarter for years but these five are doing it.

Sweta Killa headshot

Healthcare ETFs on Radar As Q1 Earnings Unfold

Further price movement of the healthcare ETFs depend on earnings releases from some big names like Pfizer (PFE), Merck (MRK), Thermo Fisher (TMO), AbbVie (ABBV), and Gilead Sciences (GILD) that dominate returns.

This is Why AbbVie (ABBV) is a Great Dividend Stock

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Strong New Drugs Sales to Aid AbbVie's (ABBV) Q1 Earnings

AbbVie (ABBV) is expected to have witnessed a recovery in demand trends for new drugs amid improving global economies. However, resurgence of COVID-19 cases is likely to have hurt sales of physician-administered drugs.

Amgen (AMGN) Q1 Earnings, Sales Miss on Low Prices, Stock Down

Amgen (AMGN) misses Q1 estimates for both earnings and sales. Shares decline in after-hours trading.

Editas (EDIT) to Report Q1 Earnings: What's in the Cards?

On Editas' (EDIT) first-quarter earnings call, investor focus is expected to be on the company's progress with the development of its lead pipeline candidate - EDIT-101.

AbbVie (ABBV) Gains But Lags Market: What You Should Know

In the latest trading session, AbbVie (ABBV) closed at $111.39, marking a +0.01% move from the previous day.

What's in the Cards for AbbVie (ABBV) This Earnings Season?

Higher demand for its growth drugs is likely to have offset generic competition for Humira in the United States to boost AbbVie's (ABBV) first-quarter sales.

J&J (JNJ) Q1 Earnings Top, COVID-19 Vaccine Brings $100M Sales

J&J (JNJ) beats first-quarter 2021 estimates for both earnings and sales. It boosts quarterly dividend by 5%.

AbbVie (ABBV) Gains As Market Dips: What You Should Know

AbbVie (ABBV) closed at $108.61 in the latest trading session, marking a +0.65% move from the prior day.

Anthem (ANTM) to Report Q1 Earnings: What's in its Store?

Anthem's (ANTM) first-quarter earnings to reflect better revenues and higher membership.

Will Solid Pharma Unit Performance Drive J&J (JNJ) Q1 Earnings?

In J&J's (JNJ) Pharma segment, its oncology drugs, Imbruvica and Darzalex as well as psoriasis treatment drug, Stelara, are likely to have driven sales growth.

Tracey Ryniec headshot

Screening for Triple Threat Stocks: Value, Growth and Dividends

Is it possible for investors to find cheap stocks that have double digit growth and that also pay a great dividend yield?

Will J&J (JNJ) Kickstart Pharma Q1 Earnings With a Beat?

J&J's (JNJ) Pharma segment is expected to have performed above market while moderate procedural disruption might have hurt the Medical Devices segment in the first quarter.

Sheraz Mian headshot

Top Research Reports for Home Depot, Toyota & IBM

Today's Research Daily features new research reports on 16 major stocks, including The Home Depot (HD), Toyota Motor (TM), and International Business Machines (IBM).

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

AbbVie (ABBV) closed at $108.22 in the latest trading session, marking a -0.03% move from the prior day.